HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...

Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...

HeartBeam's 1st synthesized 12-lead ECG cleared by FDA, enabling cable-free at-home arrhythmia assessment with launch set for 2026.

HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac ...

Santa Clara–based HeartBeam is developing a cable-free, credit-card-sized ECG recorder that captures 3D cardiac signals and synthesizes them into a diagnostic-quality 12-lead ECG. The platform’s ...

HeartBeam (BEAT) announced that the FDA has granted 510(k) clearance for the company’s 12-lead electrocardiogram synthesis software for the ...

Beginning in February, Kern County will become the first in the state to equip all EMS providers with handheld, AI-enabled 12 ...

Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, ...

Secures FDA 510(K) Clearance For 12-Lead ECG Synthesis Software Following Successful Appeal. HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through ...